ATRA - Why Atara Biotherapeutics Shares Are Plummeting Today | Benzinga
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) shares are trading lower after the company said that primary analysis data from its Phase 2 EMBOLD study of ATA188 in non-active progressive multiple sclerosis (PMS) did not meet the primary endpoint of confirmed disability improvement (CDI) by expanded disability status scale (EDSS) at 12 months compared to placebo.
"We are surprised and deeply disappointed with the results of EMBOLD, particularly for the MS patient community which is in urgent need of new treatment options," said Pascal Touchon, President and Chief ...